Blockchain Registration Transaction Record

TransCode Therapeutics to Host First Live R&D Webcast on June 18, 2026

TransCode Therapeutics announces first live R&D webcast on June 18, 2026, highlighting Phase 2a trial of TTX-MC138 in colorectal cancer. Learn about updates to its RNA therapy pipeline.

TransCode Therapeutics to Host First Live R&D Webcast on June 18, 2026

This news matters because it provides a window into TransCode's progress with TTX-MC138, a novel RNA therapeutic targeting metastatic cancer. For investors and patients, the Phase 2a trial results could signal a breakthrough in treating colorectal cancer and other aggressive tumors. The webcast offers transparency and insight into the company's strategy and pipeline, which could influence investment decisions and patient hope for new treatments.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x49733140985d1a944cf7b72d1473930c706eb07100bbb5a25a4b52a154125ace
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintwamciO7B-5a0742afbf9d6178230e1da7cfe1a698